Michelle Xia (#2945)
We focus on science and biology and the most advanced technology. I think that makes the difference.
- $ 1 B
- Biotech
- United States
- F
- 59 Years
Rest in Peace Ask Jeeves, every search comes to an end
County commissioners call on lawmakers to up funding for 911 dispatch systems
Spirit Airlines Is Going Out Of Business; Effective IMMEDIATELY
Pokémon Scalpers Selling Limited-Edition Pop-Tarts For Ridiculous Prices
Bennett says Netanyahu gov't 'boycotting' West Bank settlements amid Carrefour subsidy deal
Golf gear on sale now: Up to 65% off adidas, 45% off Puma, 15% off Mizuno, more
Families across the US can't find childcare — this map shows where it's worst
Median sales surge 61% in a Queens neighborhood that’s now the fifth priciest in NYC
Greg Brockman says his stake in OpenAI is worth nearly $30 billion
TeraWulf Announces Participation in Upcoming Investor and Industry Conferences
About Me
Michelle Yu Xia is cofounder, chairwoman and CEO of China-based biotech firm Akeso, which has multiple approved drugs in China to treat cancer. Akeso has captured attention in the biotech world because one of its drugs outperformed Merck's bestseller Keytruda in a head to head Phase 3 trial in 2024. The success of that Akeso drug, ivonescimab, drove up the price of Akeso's shares; the company is listed on the Hong Kong Stock Exchange. Prior to Akeso, Xia worked in research and at U.S. biotech firms for a dozen years starting in the mid 1990s and obtained U.S. citizenship while in America. Akeso licensed its most promising cancer drug to Miami-based firm Summit Therapeutics in 2022 for markets including the U.S., Europe and Japan.
Achievements
Career Highlights
A snapshot of the defining milestones, leadership decisions, and breakthroughs that shaped Michelle Xia’s rise and global influence.
Wealth Growth
Net Worth Growth Over Time
Tracking Michelle Xia’s net worth journey over the years, highlighting key growth phases and financial milestones.
© Iconic Billionaires